Fortrea Completes Expansion of Clinical Pharmacology Solutions Following Targeted Investments at its Four Clinical Research Units in U.S. and U.K.

DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed a multi-year effort to expand its clinical pharmacology solutions and capacity, which are now fully available for customers. The expansion includes a 100,000 square feet state-of-the-art facility in Leeds, U.K. as well as approximately 20,000 square feet of new or renovated space, adding capacity and capabilities across its clinical research units (CRUs) in Dallas, Texas; Daytona, Florida; and Madison, Wisconsin.

“The increasing complexity of clinical pharmacology studies demands fit-for-purpose infrastructure, experience and expertise to protect the safety of study participants and the integrity of critically important data,” said Oren Cohen, M.D., Fortrea’s president of Clinical Pharmacology and chief medical officer. “Our integrated platform of services includes best-in-class infrastructure and experienced professionals who are fully dedicated to clinical pharmacology, including physicians, nurses, clinical scientists, CRAs and pharmacokineticists. The investments we have made target the capabilities and capacity that customers need to accurately assess early pipeline candidates and speed those with promise to later-phase development and ultimately to patients who need them.”

Facility enhancements following the completed expansion include Fortrea’s new CRU in Leeds as well as purpose-built rooms in Madison and Daytona designed for flexibility in executing complex early phase clinical studies. Improvements in recreational, living and “work-from-home” spaces at Fortrea CRUs have been constructed to enhance the experience of volunteers participating in research at the sites.

The expansion of Fortrea’s early clinical development pharmacy services facilities includes new state-of-the-art cGMP pharmacies in the Leeds and Daytona CRUs. All Fortrea CRUs will now have cGMP pharmacies within them. This enables on-site manufacture of sterile and non-sterile drug product. The design of its GMP-compliant facilities provides safe handling and delivery of GMP-quality drug product for the unique demands of clinical pharmacology studies, focusing on efficiency and flexibility with the level of controls expected by regulatory authorities and sponsors.

Enhancements in science and technology include the addition of artificial intelligence-enabled programs that optimize bed space utilization and clinic scheduling, and the application of failure modes and effects analysis to de-risk study execution before a study begins. Following investments in data collection systems, all clinical pharmacology study data collected within Fortrea’s CRUs are input directly into a digital bedside data capture system, which can also be used as an efficient electronic data capture solution.

“I believe Fortrea’s early clinical development solutions set a new standard for what the research industry should expect from its partners,” said Dr. Cohen. “I’m so proud of this team and know they will also benefit from the changes we have made. Just as they are inspired by our mission of bringing life-changing treatments to patients faster, I’m inspired by their dedication each day as we deliver solutions to our customers.”

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services.

Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements in this press release, particularly those relating to the anticipated financial and other benefits, including, but not limited to, whether the investments at clinical research units in U.S. and U.K. will add capacity, improve therapeutic capabilities, enhance experience for study volunteers, speed development to later-phase trials and improve the integrity of data and whether the addition of artificial intelligence-enabled programs will optimize bed space utilization and clinic scheduling, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company’s control. Actual results could differ materially from expectations expressed or implied in the forward-looking statements if one or more of the underlying assumptions or expectations prove to be inaccurate or are unrealized. Important factors that could cause actual results to differ materially from such expectations are and will be detailed in Fortrea’s registration statement on Form 10 initially filed with the SEC on May 15, 2023 (as amended and further supplemented), Fortrea’s quarterly report on Form 10-Q filed with the SEC on August 14, 2023, and in Fortrea’s other filings with the SEC. These forward-looking statements are based on management’s current expectations and are subject to certain risks, uncertainty and changes in circumstances. Fortrea does not undertake responsibility for updating these statements, and these statement speak only as of the date of this press release.

Fortrea Contacts:

Fortrea Media: Sue Zaranek – 919-943-5422, media@fortrea.com
Fortrea Media: Kate Dillon – 646-818-9115, kdillon@prosek.com
Fortrea Investors: Hima Inguva – 877-495-0816, hima.inguva@fortrea.com 


Fortrea Completes Expansion of Clinical Pharmacology Solutions Following Targeted Investments at its Four Clinical Research Units in U.S. and U.K.

THỦ THUẬT HAY

6 ứng dụng chụp ảnh màn hình hữu ích dành cho macOS

Theo mặc định, macOS có khả năng chụp màn hình khá ấn tượng, nhưng nếu bạn cần chụp nhiều màn hình, bạn sẽ bắt đầu nhận thấy những hạn chế của nó. Hãy xem các tùy chọn của bên thứ ba sau để mở rộng bộ công cụ chụp màn

Hướng dẫn thanh toán QR Pay qua Vietcombank

Vietcombank chính thức ra mắt phiên bản mới của dịch vụ Ngân hàng trên điện thoại di động VCB-Mobile B@nking.Cho phép khách hàng quản lý tài khoản, chuyển tiền, nạp tiền cho điện thoại, thanh toán hóa đơn dịch vụ thuận

7 thay đổi nổi bật của Microsoft Edge mới trên Windows 10 Fall Creators Update

Microsoft Edge được giới thiệu các tính năng bổ sung và một số tinh chỉnh nhỏ với Windows 10 Fall Creators Update và sau đây là những gì bạn cần biết.

Cách sử dụng một số tính năng cơ bản đáng giá của Calculator

Calculator là ứng dụng máy tính thông dụng trên iPhone. Kể từ lần ra mắt đầu tiên tới nay, ứng dụng đã có nhiều thay đổi, nhưng tính năng cốt lõi của nó vẫn giữ nguyên. Mục đích của Calculator là giúp người dùng cộng,

Cách thay đổi ngôn ngữ trên trình duyệt Cốc Cốc

Trên trình duyệt Cốc Cốc theo mặc định, ngôn ngữ sử dụng của trình duyệt sẽ là Tiếng Việt. Tuy nhiên nếu bạn muốn thêm ngôn ngữ khác cho trình duyệt thì làm thế nào?

ĐÁNH GIÁ NHANH

Giải đáp thắc mắc có nên mua Xiaomi 11 Lite 5G NE?

Mới đây, Xiaomi vừa chính thức trình làng mẫu smartphone mới nhất có tên gọi Xiaomi Mi 11 Lite 5G NE. Vậy sản phẩm này được trang bị những tính năng gì hấp dẫn, có nên mua Xiaomi 11 Lite 5G NE ngay khi lên kệ không?

Đánh giá nhanh Kia Rondo - Mẫu xe gia đình tại Việt Nam

AutoExpress - Mẫu xe MPV Kia Rondo được giới thiệu tại Việt Nam để thay thế cho dòng xe Carens với giá bán từ 690 triệu đồng.

Đánh giá Zenfone 5Z: Cấu hình “khủng” cùng nhiều tính năng ấn tượng

Điểm nổi bật nhất trên sản phẩm chính là thiết kế không viền, với màn hình được mở rộng lên sát cạnh trên, chỉ chừa lại một phần nhỏ viền dưới. Đáng chú ý cạnh trên màn hình của sản phẩm cũng chừa vị trí để đặt cảm